Keith Rubin, MD

Chief Executive Officer
ILiAD Biotechnologies
Weston, Florida, United States

Disclosure(s): ILiAD Biotechnologies: Board Member, Ownership Interest, Stocks/Bonds (Private Company)

Presentation(s):

• 596 - Immunogenicity and Safety of BPZE1, an Intranasal Live Attenuated Pertussis Vaccine, Evaluated With and Without Tdap in Healthy Children 6 to 17 Years Old: A Phase 2b, Randomized, Active-Controlled Study

  Saturday, October 19, 2024
  2:45 PM – 3:00 PM US PT